These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 16401719)

  • 1. Acute tumor lysis syndrome after thalidomide therapy in advanced hepatocellular carcinoma.
    Lee CC; Wu YH; Chung SH; Chen WJ
    Oncologist; 2006 Jan; 11(1):87-8; author reply 89. PubMed ID: 16401719
    [No Abstract]   [Full Text] [Related]  

  • 2. Acute tumor lysis syndrome after transarterial chemoembolization for well-differentiated hepatocellular carcinoma with neuroendocrine features.
    Wang K; Chen Z
    Onkologie; 2010; 33(10):532-5. PubMed ID: 20926901
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and tolerability of low-dose thalidomide as first-line systemic treatment of patients with advanced hepatocellular carcinoma.
    Yau T; Chan P; Wong H; Ng KK; Chok SH; Cheung TT; Lam V; Epstein RJ; Fan ST; Poon RT
    Oncology; 2007; 72 Suppl 1():67-71. PubMed ID: 18087184
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I and pharmacokinetic study of oral thalidomide in patients with advanced hepatocellular carcinoma.
    Shiah HS; Chao Y; Chen LT; Yao TJ; Huang JD; Chang JY; Chen PJ; Chuang TR; Chin YH; Whang-Peng J; Liu TW
    Cancer Chemother Pharmacol; 2006 Nov; 58(5):654-64. PubMed ID: 16520988
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thalidomide for advanced hepatocellular carcinoma: is this a real alternative?
    Wadler S
    Cancer; 2005 Jan; 103(1):1-4. PubMed ID: 15565637
    [No Abstract]   [Full Text] [Related]  

  • 6. Results of three-dimensional conformal radiotherapy and thalidomide for advanced hepatocellular carcinoma.
    Hsu WC; Chan SC; Ting LL; Chung NN; Wang PM; Ying KS; Shin JS; Chao CJ; Lin GD
    Jpn J Clin Oncol; 2006 Feb; 36(2):93-9. PubMed ID: 16517834
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thalidomide in advanced hepatocellular carcinoma as antiangiogenic treatment approach: a phase I/II trial.
    Pinter M; Wichlas M; Schmid K; Plank C; Müller C; Wrba F; Peck-Radosavljevic M
    Eur J Gastroenterol Hepatol; 2008 Oct; 20(10):1012-9. PubMed ID: 18787470
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor Lysis Syndrome Due to Targeting of Hepatocellular Carcinoma Associated with Chronic Myelomonocytic Leukemia.
    Okay M; Çetik S; Haznedaroğlu İC
    Turk J Haematol; 2019 Aug; 36(3):218-219. PubMed ID: 31067853
    [No Abstract]   [Full Text] [Related]  

  • 9. Thalidomide-induced severe facial erythema in a patient with hepatocellular carcinoma.
    Chiou CC; Shih IH; Chang YC; Lee JC; Kuo SC; Hong HS; Yang CH
    Int J Clin Pract; 2007 Aug; 61(8):1415-7. PubMed ID: 17627717
    [No Abstract]   [Full Text] [Related]  

  • 10. Cytolysis following chemoembolization for hepatocellular carcinoma.
    Wigmore SJ; Madhavan KK; Redhead DN; Garden OJ
    Br J Surg; 1999 Aug; 86(8):1100. PubMed ID: 10498431
    [No Abstract]   [Full Text] [Related]  

  • 11. Treatment with inhibitors of angiogenesis in advanced hepatocellular carcinoma: a new tool in our hands or simply a hope?
    Cipriani G; Mazzanti R
    Dig Liver Dis; 2005 Apr; 37(4):230-1. PubMed ID: 15788205
    [No Abstract]   [Full Text] [Related]  

  • 12. Tumor lysis syndrome at the beginning of thalidomide therapy for multiple myeloma.
    Cany L; Fitoussi O; Boiron JM; Marit G
    J Clin Oncol; 2002 Apr; 20(8):2212. PubMed ID: 11956286
    [No Abstract]   [Full Text] [Related]  

  • 13. Tumor Lysis Syndrome: A Serious Complication of Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma.
    Jiang RD; Jian WC; Jin N; Zhang ZL; Li T
    Am J Med; 2016 Sep; 129(9):e173-6. PubMed ID: 27155110
    [No Abstract]   [Full Text] [Related]  

  • 14. Tumour Lysis Syndrome: a Rare Complication of Trans-Arterial Chemo-Embolisation with Doxorubicin Beads for Hepatocellular Carcinoma.
    Katiman D; Manikam J; Goh KL; Abdullah BJ; Mahadeva S
    J Gastrointest Cancer; 2012 Sep; 43 Suppl 1():S187-90. PubMed ID: 22692948
    [No Abstract]   [Full Text] [Related]  

  • 15. Antiangiogenic therapy combined with TACE - more beneficial therapeutic effect in HCC.
    Wang Z; Li Z
    Aliment Pharmacol Ther; 2010 May; 31(10):1153-4. PubMed ID: 20518755
    [No Abstract]   [Full Text] [Related]  

  • 16. Multi-centre phase II trial of Thalidomide in the treatment of unresectable hepatocellular carcinoma.
    Chuah B; Lim R; Boyer M; Ong AB; Wong SW; Kong HL; Millward M; Clarke S; Goh BC
    Acta Oncol; 2007; 46(2):234-8. PubMed ID: 17453375
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor lysis syndrome following thalidomide and dexamethasone therapy for newly diagnosed multiple myeloma.
    Huston A; Brown J; Roodman GD
    Exp Hematol; 2006 Dec; 34(12):1616. PubMed ID: 17157156
    [No Abstract]   [Full Text] [Related]  

  • 18. Salvage therapy for hepatocellular carcinoma with thalidomide.
    Wang TE; Kao CR; Lin SC; Chang WH; Chu CH; Lin J; Hsieh RK
    World J Gastroenterol; 2004 Mar; 10(5):649-53. PubMed ID: 14991931
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low-dose thalidomide treatment for advanced hepatocellular carcinoma.
    Hsu C; Chen CN; Chen LT; Wu CY; Yang PM; Lai MY; Lee PH; Cheng AL
    Oncology; 2003; 65(3):242-9. PubMed ID: 14657598
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of thalidomide in patients with hepatocellular carcinoma.
    Chiou HE; Wang TE; Wang YY; Liu HW
    World J Gastroenterol; 2006 Nov; 12(43):6955-60. PubMed ID: 17109516
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.